Heat Biologics Provides Second Quarter 2021 Business Update
August 11, 2021 16:05 ET
|
Heat Biologics
DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the...
Heat Biologics Announces Groundbreaking for New San Antonio Facility
August 09, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Joins Russell Microcap® Index
June 28, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., June 28, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
June 23, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., June 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
June 04, 2021 09:00 ET
|
Heat Biologics
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
May 20, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit
May 19, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
May 10, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs
May 05, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the...
Heat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
April 26, 2017 07:00 ET
|
Heat Biologics
DURHAM, N.C., April 26, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...